On November 28, 2017 Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") reported new data in acute myeloid leukemia (AML) research, including preliminary results from a Phase 1 study of the investigational agent gilteritinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed AML, it will present at the 2017 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting (Press release, Astellas Pharma US, NOV 28, 2017, View Source [SID1234522270]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The wide selection of abstracts showcases the company’s full-scale development program across the FLT3 mutation-positive (FLT3mut+) AML care continuum—from newly-diagnosed to relapsed or refractory patients.

"This research further shows FLT3 mutations are one of the most commonly occurring mutations in AML, and we are pleased to be continuing our commitment to addressing the needs of AML patients," said Steven Benner, M.D., senior vice president and global therapeutic area head, Oncology Development, Astellas. "Further, we’re pleased to showcase additional data that examines the cost of care as well as healthcare utilization in the current treatment of FLT3mut+ AML."

The following abstract will be presented during an oral presentation session:

Title: Preliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) (Abstract 722)

Presenter: Keith W. Pratz, M.D., John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

Session Date/Time: Monday, December 11, 3:00 p.m. EST
Location: Building B, Level 5, Murphy BR 1-2
In addition to the oral presentation, Astellas will present the following five abstracts during poster sessions:

Title: Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-mut and FLT3-wt Acute Myeloid Leukemia: A Multi-country Medical Chart Study (Abstract 2186)

Lead Author: James D. Griffin, M.D.

Session Date/Time: Saturday, December 9, 5:30-7:30 p.m. EST
Location: Building A, Level 1, Hall A2
Title: Comparative Assessment of FLT3 Variant Allele Frequency by Capillary Electrophoresis and Next-Generation Sequencing in FLT3mut+ Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) who Received Gilteritinib Therapy (Abstract 1411)

Lead Author: Catherine C. Smith, M.D.

Session Date/Time: Saturday, December 9, 5:30-7:30 p.m. EST
Location: Building A, Level 1, Hall A2
Title: Real-World Occurrence of Symptoms and Toxicities and Associated Cost Implications in Acute Myeloid Leukemia (AML) Treatment Episodes: A Retrospective Database Analysis in the U.S. (Abstract 2118)

Lead Author: Bhavik Pandya, Pharm.D.

Session Date/Time: Saturday, December 9, 5:30-7:30 p.m. EST
Location: Building A, Level 1, Hall A2
Title: Evaluation of the Impact of Minimal Residual Disease, FLT3 Allelic Ratio, and FLT3 Mutation Status on Overall Survival in FLT3 Mutation-Positive Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the CHRYSALIS Phase 1/2 Study (Abstract 2705)

Lead Author: Mark J. Levis, M.D., Ph.D.

Session Date/Time: Sunday, December 10, 6:00-8:00 p.m. EST
Location: Building A, Level 1, Hall A2
Title: Economic Burden of Treatment Episodes in Acute Myeloid Leukemia (AML) Patients in the U.S.: A Retrospective Analysis of a Commercial Payer Database (Abstract 4694)

Lead Author: Bruno C. Medeiros, M.D.

Session Date/Time: Monday, December 11, 6:00-8:00 p.m. EST
Location: Building A, Level 1, Hall A2
About Gilteritinib
Gilteritinib is an investigational compound that has demonstrated inhibitory activity against FLT3 internal tandem duplication (ITD) as well as FLT3 tyrosine kinase domain (TKD), two common types of FLT3 mutations that are seen in approximately one-third of all patients with AML. Further, gilteritinib has also demonstrated inhibition of the AXL receptor in AML cell lines, which has been reported to be associated with therapeutic resistance. Astellas is currently investigating gilteritinib in various AML patient populations through several Phase 3 trials. Visit AstellasAMLTrials.com to learn more about ongoing gilteritinib clinical trials.

Gilteritinib was discovered through a research collaboration with Kotobuki Pharmaceutical Co., Ltd., and Astellas has exclusive global rights to develop, manufacture and potentially commercialize gilteritinib. Gilteritinib has been granted Orphan Drug designation and Fast Track designation by the U.S. FDA, and SAKIGAKE designation by the Japan Ministry of Health, Labor and Welfare.

The safety and efficacy of the agent discussed herein are under investigation and have not been established. There is no guarantee that the agent will receive regulatory approval and become commercially available for the uses being investigated. Information about pharmaceutical products (including products currently in development), which is included in this press release are not intended to constitute an advertisement or medical advice.